Chugai Pharmaceutical Co., Ltd. is a Japan-based biopharmaceutical company that discovers, develops, manufactures, and commercializes prescription medicines, with core strengths in oncology, immunology, and hematology. The company has been a member of the Roche Group since 2002, with Roche holding a majority stake, and it collaborates closely with Roche/Genentech on global development and commercialization.
Chugai is recognized for its expertise in biologics, including monoclonal and bispecific antibodies, and for proprietary antibody engineering platforms. Its activities span early research through clinical development, regulatory approvals, and production of biologics and small-molecule therapeutics. Headquartered in Tokyo, Chugai serves the Japanese market while contributing originator science and products to international markets through its partnership network.